In summary, we generated a de novo KI mouse model to demonstrate LINK‐A to be an effective RNA‐based therapeutic drug target to treat HFD‐induced obesity, evidenced by the nucleic acid drug ASO preventing the developing HFD‐induced obesity in LINK‐A KI mice. Here, LINC01139 is linked to obesity due to melanocortin 4 receptor deficiency.